Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Pancreatic cancer – Keep reading Earl Groce’s success with CPI-613

No sign of cancer!

Groce has been a part of a clinical trial since his diagnosis four-plus years ago and the results have been tremendous –just recently, his MRI and CT scan revealed continued good results – no sign of cancer. His CA 19-9 levels remain in a normal range – also a good sign.

At 72, Groce has had 98 rounds of chemotherapy through a clinical trial for CPI-613, a targeted therapy aimed at cancer cell metabolism. He receives the test drug in addition to the Standard of Care protocol which is FOLFIRINOX, a combination of three chemotherapeutic agents. He joined the clinical trial as a phase I study participant. The study is currently in an advanced phase, phase III.

Gross is undoubtedly free of a disease that is known to be extremely aggressive due to the fact that he participated in the study. Because of this, he received an innovative drug that was not available to other patients not participating in the study and would go on for several years until the final approval of CPI-613, which would then be available to all patients.

Pancreatic cancer patients who participate in clinical research have better outcomes. Every treatment available today was approved through a clinical trial. The Pancreatic Cancer Action Network (PanCAN) strongly recommends clinical trials at diagnosis and during every treatment decision.

“If you get a chance to enroll in a clinical trial, please consider it. Do it for your sake and the sake of future patients”, says Groce.

About Pancreatic Cancer

Pancreatic cancer occurs when cancer cells develop in the tissues from which the pancreas is made.

This type of cancer is aggressive, since most of the patients are diagnosed in an advanced stage, where the disease is considered incurable, for the most part.

Pancreas cancer is hard to diagnose early since its symptoms do not usually appear in early stages.

In many cases until the patient is diagnosed with a pancreatic cancer there are already metastases elsewhere in the body (stage 4 metastatic pancreatic cancer).

The patient’s life expectancy is poor and currently stands on less than one year; this is with the support of the standard treatments.

To improve patients’ chances, the American Society for Clinical Oncology, ASCO, that includes various specialists in its panel, such as oncologists, radiologists, gastrologists among others, guides oncologists to inform pancreatic cancer patients in all topics related to clinical trials in every stage of their disease.

The National Cancer Institute, NCI, of the United States, stresses that for pancreatic cancer patients, the preferred treatment option is to join one of the many clinical trials around the world and thus increase the chances of success over the standard protocols.

Contact us to access the best matched treatments for YOU

TRIAL•IN Pharma

Do not give up on life!

Contact us 24/7 for free service matching:

Call center +44.2082.426.039

 

For further reading

To get a personal free assessment to our service please in fill in your details and we will get back to you shortly

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Close Menu